Renewed Focus on Mifepristone with Trump’s FDA Nominee

The head of the longest-running pro-life organization in the U.S. remarked that Dr. Heidi Overton, the FDA nominee chosen by President Donald Trump, may bring increased scrutiny to mifepristone, a medication currently under review by federal authorities for safety concerns.

John Mize, CEO of Americans United for Life (AUL), mentioned that he has had several discussions with Overton, emphasizing her strong pro-life stance. She is currently a deputy assistant to Trump, focusing on domestic policy.

“I think she’s going to bring a level of objectivity to the mifepristone discussion that will highlight the damage this drug can inflict on women,” Mize expressed during a recent interview. He seems quite hopeful, stating that they are “optimistic” Overton will serve as a pro-life FDA commissioner.

Her nomination comes shortly after an 18-year-old from North Carolina was accused of using mifepristone and its companion drug misoprostol to end a pregnancy at 31 weeks, far exceeding the FDA’s approved use of mifepristone within 10 weeks.

Proposed Legislation to Revoke FDA Approval

Mize has been leading AUL for about two and a half years, but the organization has opposed abortion, euthanasia, and assisted suicide since its founding in 1971. He has voiced strong faith in Overton as the right candidate for the FDA, citing her background in government and medical science. Should she be confirmed, she would oversee the agency that regulates abortion medications such as mifepristone.

Mifepristone carries a boxed warning, the strictest from the FDA, due to associated risks of severe infections and bleeding.

In response to limitations imposed during the COVID-19 pandemic, the FDA eased the in-person dispensing requirement for this medication in 2021, which later became permanent after assessing safety data. Now, patients aren’t always required to attend an in-person consultation before getting a prescription, which can be done through telehealth.

Mize advocates for stricter regulations on these procedures, insisting that women should have to meet with a doctor face-to-face before receiving the medication.

Opposition to Mifepristone

“Dr. Overton and I share a very similar perspective that the drug is dangerous, particularly when unregulated,” Mize conveyed. He believes Overton grasps the clinical risks involved with using a drug that carries a strong FDA warning, especially when it’s being mailed to patients.

Overton has previously criticized mifepristone and other abortion drugs, citing statistics that show their increasing use in abortions since the Supreme Court’s decision to overturn Roe v. Wade. In a policy brief for a conservative think tank earlier this year, she chastised federal officials for broadening access to abortion pills, claiming the COVID-19 pandemic was misused as justification for such policies.

She labeled mifepristone and misoprostol, a drug that induces labor, as problematic when shipped to patients.

The two drugs function together to terminate early pregnancies: mifepristone halts progesterone production, crucial for maintaining pregnancy, while misoprostol causes uterine contractions to expel the fetus.

Overton expressed the belief that abortion poses risks not only to women but also impacts children and society, emphasizing the need to reevaluate and possibly halt the movement to normalize abortions.

Mize referenced a recent study from a conservative group showing concerning statistics associated with mifepristone use. Though the study’s methodology faced critique, he highlighted its importance in depicting the potential dangers women might face.

He hopes that if confirmed, Overton will consider imposing stricter measures on mifepristone and possibly reinstating a requirement for doctors’ in-person consultations prior to prescriptions. However, Mize cautioned against expecting immediate sweeping changes, portraying Overton as someone who might take a methodical approach to her role.

Moreover, he acknowledged that while not all evidence is available yet, his personal view leans toward removing mifepristone from the market. “From my viewpoint, any medication that interferes with the right to life and results in death can’t be something we should endorse,” Mize remarked. He pointed out that culturally, the discourse might not be ready for that conclusion.

Overton’s confirmation hearing has yet to be scheduled but is anticipated to occur after the Senate reconvenes in mid-September.